A systematic review and meta-analysis of traditional insect Chinese medicines combined chemotherapy for non-surgical hepatocellular carcinoma therapy

Zhaofeng Shi, Tiebing Song, Yi Wan, Juan Xie, Yiquan Yan, Kekai Shi, Yongping Du & Lei Shang

On the background of high morbidity and mortality of hepatocellular carcinoma (HCC) and rapid development of traditional Chinese medicine (TCM), we conducted a systematic review and meta-analysis of randomized clinical trials (RCTs) according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement to assess the clinical effectiveness and safety of traditional insect Chinese medicine and related preparation for non-surgical HCC. RCTs were searched based on standardized searching rules in mainstream medical databases from the inception up to May 2016. Ultimately, a total of 57 articles with 4,651 patients enrolled in this meta-analysis. We found that traditional insect Chinese medicine and related preparation combined chemotherapy show significantly effectiveness and safety in objective response rate ($P < 0.001$), survival time extension [12 months ($P < 0.001$); 18 months ($P < 0.001$); 24 months ($P < 0.001$); 36 months ($P < 0.001$)], amelioration for life quality [QoL scores improvement ($P < 0.001$); KPS improvement ($P < 0.001$); AFP improvement ($P < 0.001$)] and reduction of therapeutic toxicity [WBC decrease ($P = 0.04$); gastrointestinal adverse reactions ($P < 0.001$)]. In conclusion, traditional insect Chinese medicine and related preparations could be recommended as auxiliary therapy combined chemotherapy for HCC therapy.

Hepatocellular carcinoma (HCC), a common kind of primary liver cancer (PLC), ranks as the sixth most common neoplasm and the third most frequent reason for cancer death\(^1\). A report by the World Health Organization (WHO) showed that HCC has become a major health problem nowadays, and the incidence of HCC is increasing as time goes on\(^2\). It was estimated that 748,300 new liver cancer cases and 695,900 liver cancer deaths occurred worldwide in 2008\(^4\). The morbidity and mortality of HCC reached a new peak in 2012 with 782,000 new cases and 745,000 death cases all over the world\(^4\). The East and South-East Asia along with the Middle and Western Africa have the highest HCC rates compared with other places around the world\(^5\). Moreover, the rate of HCC in developed countries, such as the United States, has increased rapidly in recent years\(^6\).

HCC is the major cause of death among patients who had been diagnosed with cirrhosis\(^7\). It is estimated that the combined effectiveness of the chronic hepatitis C virus (HCV) and the hepatitis B virus (HBV) infections takes up over 80% of liver cancer cases around the world\(^6\). With respect to HCC diagnosis, if tumor (lesions $\geq 10$mm) shows the typical feature on computed tomography (CT) or magnetic resonance images

\(^1\)Department of Traditional Chinese Medicine, Xijing Hospital Affiliated to Fourth Military Medical University, Xi’an, 710032, China. \(^2\)Department of Orthopaedics, Xi’an City Hospital of Traditional Chinese Medicine, Xi’an, 710021, China. \(^3\)Department of Health Services, the Public Health Faculty of Traditional Chinese Medicine, Xi’an, 710032, China. \(^4\)Department of Health Statistics, the Public Health Faculty of Fourth Military Medical University, Xi’an, 710032, China. \(^5\)Department of Engineering, Carnegie Mellon University, Pittsburgh, PA15213, United States. Zhaofeng Shi, Tiebing Song and Yi Wan contributed equally to this work. Correspondence and requests for materials should be addressed to L.S. (email: shanglei@fmmu.edu.cn)

Received: 17 January 2017
Accepted: 12 May 2017
Published online: 28 June 2017
(MRI), no further investigation will be required. If not, the biopsy specimen is required\(^9\). The measurement of alpha-fetoprotein (AFP) may not be useful in clinical practice and will not affect the formulation of final treatment strategy\(^8\).

Although HCC has a poor prognosis so far, ultrasonography surveillance can diagnose HCC at early stage (single tumors or as many as 3 nodules \(\leq 3\) cm) when the tumor could be cured by resection, liver transplantation, or ablation, and the 5-year survival rate can exceed 50%\(^16\). For the patients at the intermediate or end stage of HCC, palliative methods such as transcatheter hepatic arterial chemoembolization (TACE) or intravenous chemotherapy are appropriately approaches\(^11\). Those methods are limited by their toxicities, drug resistance, and miscellaneous adverse effects for end stage patients, meanwhile the survival benefits are still not proven\(^12\). Given this limitation of therapy on HCC, complementary and alternative medicine (CAM) has been increasingly applied to it over the past few decades. Physicians are trying to find more adjutantive or auxiliary therapies to improve patients’ quality of life or survival time and reduce side effects caused by chemotherapy.

Traditional insect Chinese medicine is an old ancient Chinese medical concept that is still used today in China. It can be recognized as the Chinese animal species medicines, including the dried medical animal bodies, the medical animal bodies without entrails, secretions and excretions of medical animals and the processing products of insects\(^15\). Owing to the various versions of the translation for TCM, we could not even find a precise translation for traditional insect Chinese medicine from a number of Chinese-English dictionaries of TCM. As a result, we adopted the word “insect” that has the same literary meaning of “animal” to replace it. The traditional insect Chinese medicine is a broad concept, while the narrow definition of it is only confined to the insect or worm drugs. It has been originally recorded in medical book named *Fifty-two patients side for the medical interpretation and practice in the Warring States period of China (475–221 BC)*\(^14\). And *Shennong's herbal classic*, one of the earliest Chinese herbal collections of TCM, deeply introduced the effects of traditional insect Chinese medicine\(^15\). Another Chinese herbal masterpiece, *Compendium of materia medica*, written by Shizhen Li, collected nearly 500 kinds of traditional insect Chinese medicines and classified them meticulously, promoting traditional insect Chinese medicine to a new peak. The modern experimental researches of traditional Chinese insect medicine have been gradually focussing on anti-tumor properties by inhibiting the proliferation of cancer cells, inducing tumor cell apoptosis and improving the immune function of the human body\(^16\).

Traditional insect Chinese medicine, as an essential component of TCM, has been widely applied in the treatment of the non-surgical HCC (at the intermediate stage and the advanced stage) for a long time with side effects a rare occurrence. Although a great number of published clinical studies have evaluated different kinds of traditional insect Chinese medicines and the related preparations combined chemotherapy for HCC\(^17–19\), the clinical efficacy and pharmacological mechanism remain unclear. No article of systematic review or meta-analysis has been conducted based on considering the traditional insect Chinese medicines as an integral part to evaluate the efficiency and safety for HCC treatment. Therefore, we conducted a systematic review and meta-analysis to investigate the evidence about traditional insect Chinese medicine and the related preparation combined chemotherapy for the clinical effectiveness and safety of non-surgical HCC.

### Materials and Methods

This systematic review and meta-analysis was conducted by order of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement\(^20\).

#### Search strategies.

Literatures were extracted from the main electronic databases including PubMed, Embase, Medline, Science Direct (SD), Web of Science, ProQuest, the Cochrane Central Register of Controlled Trials, Springerlink, Wiley Library Online, Chinese Biological Medicine Database (CBM), China National Knowledge Infrastructure (CNKI), Chinese Medical Citation Index (CMCI), WanFang Database, Chinese Scientific Journal Database (VIP), and Japan Medical Abstracts Society from their inception up to May 2016. In addition, there were no language restrictions on the literature searching.

The searching terms were performed as follows: “liver cancer,” “hepatocellular carcinoma,” “liver neoplasm,” “primary liver carcinoma,” “traditional insect Chinese medicine,” “insect drugs,” “cinobufatalin,” “huachansu,” “centipede,” “scorpion,” “leech,” “earthworm,” “cantharides,” “gecko,” “snake venom,” “grand beetle,” “aspogopous,” “gadfly,” “honeycomb,” “chemotherapy,” “interventional therapy” and “random clinical trials.” No other restrictions were performed and the free text strategy and Medical Subject Headings (MeSH) terms were conducted in the term searching process. Categories of traditional insect Chinese medicine on literature searching were derived from the classification of MeSH term in CBM database. The searching language in Chinese, English and Japanese was slightly changed based on the situation for different databases adaptation.

#### Study selection.

The study selection was conducted by two reviewers (Z.F. Shi, Y.Q. Yan) independently and disagreements were resolved by the common strategy or a third reviewer (J.Xie). Eligible studies that suited for the following criteria were included in this systematic review and meta-analysis: (1) randomized clinical trials (RCTs); (2) patients were diagnosed as non-surgical HCC (TNM stage II or above; BCLC stage B or above) by pathological results or imaging examinations; (3) participants received traditional insect Chinese medicine and related preparation combined chemotherapy in the treatment group, meanwhile chemotherapy alone in the control group; (4) evaluated outcomes including at least one of the following variables: (a) complete response rate (CR), partial response rate (PR) and CR + PR as a proportion of objective response rate; (b) quality of life (QoL) scores or Karnofsky performance scores (KPS); (c) the Child-Pugh scores; (d) major side effects resulting from traditional insect Chinese medicines or chemotherapy; (5) survival time rate (the number of participants in the treatment and the control group who were alive at 6, 12, 18, 24, 36 months). The studies were excluded if they met...
these following criteria: (a) received the Chinese herbal medicine in the control group; (b) received the irrelevant TCM therapies or western medical methods in experimental group; (c) the clinic pathologic types of liver cancer were not compatible with the HCC criteria; (d) severe clinical illnesses (such as liver or kidney disease) or infections; (e) absence or inconsistency of methods, evaluation criteria or results; (f) non-randomized clinical trials (comments, case reports, reviews, editorials, letters, et al.), articles unrelated with the topic, or duplicated articles.

Particularly, the clinical stage of HCC was identified according to the TNM staging system of the American Joint Committee on Cancer (AJCC) obtained from the National Comprehensive Cancer Network (NCCN) guideline 201524(T refers to the size of the original tumor and whether it has invaded nearby tissue; N represents nearby lymph nodes that are involved; M can be recognized as distant metastasis) or the Barcelona Clinical Liver Cancer (BCLC) system coming from the European Association for the Study of the Liver (EASL)22. For the reason of diversity and complexity of TCM therapy, traditional insect Chinese medicine and the related preparation can be obtained from some Chinese herbs that have the synergistic effects without interfering with the major function of traditional insect Chinese medicine. The imaging examination includes the methods of computed tomography (CT) or magnetic resonance imaging (MRI), showing the lesions ≥ 10mm at least. Also, CT or MRI can evaluate the CR or PR: CR means all targeted lesions disappear and pathological lymph nodus must reduce to less than 10mm at least, and PR means targeted lesions decrease 30% in the sum of diameters at least. This solid tumor response was evaluated according to the Response Evaluation Criteria in Solid Tumor (RECIST) guideline (version 1.1), which has been updated and revised by the European Cancer Organization (ECCO) in 200925. The side effects (the chemotherapy related toxicity and TCM adverse effects) included as the follows: bone marrow suppression including leukopenia, thrombocytopenia or anemia; gastrointestinal side effects including nausea, emesis, anorexia, or diarrhea; liver or kidney injury; pyrexia and pain. The dosage of traditional insect Chinese medicine and chemotherapy in experimental groups and control groups of trials was discrepant. There was no limitation for the dosage in the study searching and including.

Data extraction and quality analysis. Two reviewers (Z.F.Shi, Y.Q.Yan) extracted data independently, assessing the inclusion and exclusion criteria before based on the standardized collection. All disagreements were discussed between two reviewers mentioned before, and the final conclusion was reached after deliberation over with a third reviewer (J.Xie). The extracted characteristics comprised the following items: (1) the name of author and the year of publication; (2) sample size; (3) study design; (4) study performed areas; (5) the baseline characteristics of patients; (6) approaches and duration of treatments; (7) outcome evaluation and trials quality assessment.

The quality analysis was performed by two investigators independently (Z.F.Shi, Y.Q.Yan), using the Cochrane Collaboration’s tools for assessing the risk of bias26. This tool was conducted to evaluate the bias of studies across six domains: (1) the method of random allocation; (2) the concealment of allocation; (3) the blinding method; (4) the integrity of outcome data; (5) the outcome data of selective reports; (6) other bias sources. Every domain mentioned above was assessed by the criterion of “yes”, “no” or “unclear”. The article had 3 or more “yes” could be recognized as high quality and less than 3 “yes” should be considered as low quality.

Statistical analysis. The RevMan (version 5.2) was applied to pool and analyze data. The reviewer (Z.F.Shi) calculated the risk ratio (RR) with 95% confidence interval (CI) for the dichotomous outcomes and the standard mean difference (Std.MD) or mean difference (MD) with 95% confidence interval (CI) for the continuous outcomes respectively. Statistical heterogeneity was tested through studies by the method of $\chi^2$ statistic. It was a quantitative tool for inconsistency and could provide an estimate of variation resulted from heterogeneity. Results of $\chi^2$ statistic between 25 and 50% were regarded as low heterogeneity, 50 and 75% were moderate heterogeneity, and above 75% were high heterogeneity. It should be noted that the Cochrane Handbook (version 5.1.0) indicates the value of $\chi^2$ statistic above 50% was considered to have considerable heterogeneity. The subgroup analysis was performed to find the source of heterogeneity. A fixed effects model (applying Mantel-Haenszel method29) was conducted to pool data when the heterogeneity did not exist or moderate, while a random effects model (applying Der Simonian-Laired method30) was performed when there was obvious heterogeneity. Additionally, sensitivity analysis was further conducted to assess the stability of results and evaluate the variation of pooled data. Publication bias was assessed visually by funnel plots and calculated in Egger’s test/Begg’s test through the software named Stata (version 14.0, StataCrop LP, College Station, US)29, 30. $P$ values lower than 0.05 were judged as statistically significant for the results, representing that the study has publication bias.

Results

The flowchart of article search and selection in the meta-analysis is presented in Fig. 1. Of a total of 358 potentially relevant articles identified from 15 different electronic databases, one hundred and ninety-one studies of them were ruled out for the reason of duplication. Ninety-three publications were further excluded, after detailed screening and analyzing, for the following reasons: (a) thirty-five studies were confirmed unrelated to article topics or could not find the full-text papers even after contacting with authors; (b) ten studies were found to be systematic reviews and meta-analyses; (c) Thirty-two studies were non-clinical trials or non-randomized clinical trials; (d) Sixteen articles were unrelated to hepatocellular carcinoma or traditional insect Chinese medicine. Seventy-four full-text articles were eligible and then reviewed independently. Of 17 publications further
excluded, 11 publications were excluded because the inappropriate criteria of experimental or control group, for instance, the control group contains TCM therapy. Three publications missed sufficient data (i.e. Control group), which made the report outcomes untrustworthy. Three publications obtained irrelevant observation criteria, which seemed inconsistent with the criteria mentioned before. Overall, a total of 57 articles with 4,651 patients were enrolled in this meta-analysis.

Included articles characteristics and quality evaluation. A total of 57 publications met with the final eligibility criteria. All studies were randomized clinical trials (RCTs) and carried out in the hospitals in China. All trials were single-center studies except one performed in 3 different areas' hospitals in China. Published year of articles was between 1999 and 2015. These trials were conducted among men and women between 18 and 85 years old. There were eighteen articles clearly introduce the stage of HCC except for 2 publications including stage I hepatocellular carcinoma. The most common stage of HCC was the stage II-III based on the National Comprehensive Cancer Network (NCCN) guidelines except for 2 publications including stage I hepatocellular carcinoma. Seventeen articles clearly reported the Child-Pugh grades included class A and B. However, Child-Pugh class C was extra included in 5 articles mentioned before and Child-Pugh class A was only included in 1 article. The traditional insect Chinese medicine and the related preparation are diversified in included articles: the major insect related medicines contained as follow: cinobufotalin injection, Aidi injection, sodium cantharidinate and vitamin B6 injection, sodium norcantharidate injection, jinlong capsule, and compound cantharides capsule. The major chemotherapy plan in studies was transcatheter hepatic arterial chemoembolization (TACE), while some articles reported additional chemotherapy regimens, which included FAP (5-fluorouracil + doxorubicin + cisplatin), FAM (5-fluorouracil + doxorubicin + mitomycin), FOLFOX4 (oxaliplatin + calcium folinate + 5-fluorouracil) and 5-fluorouracil.
| Name          | Year | Group 1 | Group 2 | Sex (M/F) | Age         | Disease stage | Child-Pugh scores | KPS score | Treatment Group | Control Group | Duration |
|--------------|------|---------|---------|-----------|-------------|---------------|-------------------|-----------|----------------|---------------|----------|
| Huang W.K.   | 2013 | 41      | 41      | 44/26     | 48.54 ± 4.16 years old | II, III       | —                 | >60       | Cinobufotalin injection + TACE (OXA, EPL) | TACE (OXA, EPL) | 3 weeks   |
| Cao Y.       | 2014 | 68      | 68      | 78/58     | E:55.2 ± 7.4 years old | —             | A and B          | >50       | Compound cantharis capsule + FAP (5-FU, EPL, DDP) | FAP (5-FU, EPL, DDP) | 10 days  |
| Zeng C.S.    | 2012 | 30      | 30      | 19-Nov    | E:51.65 ± 6.92 years old | II, III       | A and B          | —         | Jinlong capsule + TACE (THP, DDP, 5-FU) | TACE (THP, DDP, 5-FU) | 60 days  |
| Deng Z.Y.    | 2015 | 25      | 24      | 29/20     | E:48.65 ± 16.12 years old | —             | —                | —         | Cinobufotalin injection + TACE (THP, DDP) | TACE (THP, DDP) | 4 weeks  |
| Dong M.E.    | 2014 | 60      | 60      | 76/44     | E:median age 55 years | —             | —                | —         | Cinobufotalin injection + TACE (GEM, DDP, 5-FU, CF) | TACE (GEM, DDP, 5-FU, CF) | 4 weeks  |
| Feng X.M.    | 2012 | 38      | 32      | 44/26     | E:52.6 ± 11.7 years old | II III        | —                | >60       | Cinobufotalin injection + POLFOX4 (OXA, 5-FU, CF) | FOLFOX4 (OXA, 5-FU, CF) | 3 rounds (2 days per round) |
| Fu Z.L.      | 2010 | 78      | 78      | 119/37    | E:median age 58 years | —             | —                | >60       | Cinobufotalin injection + TACE (5-FU, DDP, MMC) | TACE (5-FU, DDP, MMC) | 3 months |
| He S.L.      | 2012 | 26      | 25      | 37/14     | 58.8 years old | —             | A and B          | —         | Cinobufotalin injection + TACE (OXA, 5-FU, THP) | TACE (OXA, 5-FU, THP) | 2 weeks  |
| Ji J.E.      | 2015 | 25      | 22      | 36/11     | 62.3 years old | —             | —                | —         | Cinobufotalin injection + TACE (DDP, 5-FU, DOX) | TACE (DDP, 5-FU, DOX) | 4–5 weeks |
| Jia C.H.     | 2008 | 30      | 30      | 44/16     | E:54.2 ± 6.4 years old | I, II, III    | A, B and C       | >60       | Jinlong capsule + TACE (MMC) | TACE (MMC) | 3 months |
| Jiang C.Y.   | 2013 | 30      | 33      | 36/27     | E:median age 57 years | II, III       | —                | ≥60       | Jinlong capsule + TACE (5-FU, THP) | TACE (5-FU, THP) | 2 rounds (8 days per round) |

Continued
| Experimental group | Control group | Sex(M/F) | Age | Disease stage | Child-Pugh scores | KPS score | Treatment group | Control group | Notes |
|--------------------|---------------|----------|-----|--------------|-------------------|-----------|-----------------|---------------|-------|
| Ke J.41 2011       |               | 38/40   | 69/9| E:58.3 ± 11.59 years old | — | A and B | >60 | Cinobufotalin injection + TACE (5-FU, DDP, DOX) | 3 rounds (20 days per round) | 1. Clinical effectiveness | 2. Life quality | 3. Comparison of WBC, TBIL, ALT and AFP | 4. Survival at 6/12 months | 5. Complication |
| Kou C.Y.42 2011    |               | 31/31   | 40/22| E:40.5 years old | — | — | >60 | Cinobufotalin injection + TACE (HCPT, DDP, DOX) | 4 weeks | 1. Clinical effectiveness | 2. QoL scores | 3. Complication | 4. Survival at 12/24/36 months |
| Li B.43 2013       |               | 74/73   | 97/50| Median age:56.4 years | — | — | >60 | Jionl capsule + TACE (5-FU, EPI, DDP, MMC, CF) | 2 rounds (28 days per round) | 1. Clinical effectiveness | 2. Life quality | 3. Comparison of Child-pugh, Classification and WBC | |
| Li J.44 2013       |               | 43/62   | 76/29| E:45.2 ± 4.8 years old | — | A, B and C | — | Aidi injection + TACE (5-FU, THP, DDP, MMC) | 10 days | 1. Life quality | 2. Survival at 6/12/24/36 months | 3. AFP | 4. TACE times | |
| Li Q.45 2008       |               | 50/46   | 84/12| 50.2 years old | I, II, III | A and B | ≥ 60 | Cinobufotalin injection + TACE (5-FU, HCPT, DOX, MMC) | 4 weeks | 1. Clinical effectiveness | 2. Life quality | 3. Survival at 6/12/24 months | 4. Comparison of WBC, TBIL and ALT | 5. Immunological function |
| Li Q.M.46 2003     |               | 20/18   | 28-Oct| 29–65 years old | II, III | — | ≥ 60 | Qining injection + TACE (HCPT, 5-FU, EPI) | 7 days | 1. Clinical effectiveness | 2. Complication | |
| Li W.H.47 2006     |               | 19/19   | 28-Oct| 45 years old | — | — | — | Cinobufotalin injection + TACE (5-FU, DDP, MMC) | 2 rounds | 1. Life quality | 2. Clinical effectiveness | 3. Comparison of WBC and AFP | 4. Survival at 12/24 months and median survival time | 5. Complication |
| Liang B.L.48 2010  |               | 20/20   | 30-Oct| E:59 ± 6 years old | — | — | ≥ 50 | Sodium Cantharidinate and vitamin B6 + TACE (MMC, 5-FU, EPI) | 4 weeks | Comparison of liver function and blood routine examination | |
| Liang C.X.49 2015  |               | 30/30   | 34/26| E:median age 53 years | — | A and B | >80 | Sodium Cantharidinate and Vitamin B6 + TACE (5-FU, DDP, OXA, EPI) | 3–4 rounds (15 days per round) | 1. Clinical effectiveness | 2. Comparison of WBC and AFP | 3. QoL scores | |
| Liang T.41 2005    |               | 116/108 | 187/37| E:52.1 ± 9.7 years old | — | A, B and C | — | Jionl capsule + TACE (EPI, MMC, CBP) | ≥ 3 years | 1. Survival at 6/12/24/36 months | 2. Clinical effectiveness | 3. QoL scores | |
| Liang Y.50 2008    |               | 48/48   | 72/24| Median age:44.5 years | — | A, B and C | ≥ 70 | Cinobufotalin injection + TACE (EPI, DDP, 5-FU) and IFN | 2 rounds (4 weeks) | 1. Clinical effectiveness | 2. Life quality | 3. Comparison of 6/12/18 months | 4. Complication |

Continued
| Liu X.H.52 2009 | 42 | 42 | 70/14 | 48.5 years old | — | — | — | Cinobufotalin injection + TACE (5-FU, DDP, EPI) | TACE (5-FU, DDP, EPI) | 2–3 rounds (4 weeks per round) | 1. Clinical effectiveness | 2. Survival at 12/24/36 months | 3. Comparison of immune function and liver function | 4. Complication |
| Liu Y.Q.53 2010 | 38 | 44 | 72/10 | E:54.21 ± 10.32 years old | — | A and B | ≥ 60 | Cinobufotalin injection + TACE (THP, DDP, MMC) | TACE (THP, DDP, MMC) | 2–3 rounds (3 weeks per round) | 1. Lipidol deposition after TACE | 2. Clinical effectiveness | 3. Comparison of TTP | 4. Complication |
| Lu S.J.54 2014 | 30 | 30 | 33/17 | E:46.5 years old | C:47.3 years old | — | — | — | Cinobufotalin injection + THM and TACE (DDP, DOX, 5-FU) | TACE (DDP, DOX, 5-FU) | 30 days | 1. Clinical effectiveness | 2. Life quality | 3. Survival at 6/12/24 months | 4. Complication |
| Peng W.D.55 2011 | 40 | 40 | 43/37 | E:45.0 ± 13.5 years old | C:44.0 ± 13.9 years old | II, III | — | ≥ 50 | Compound cantharis capsule + FAP (5-FU, EPI, DDP) | FAP (5-FU, EPI, DDP) | 10 days | 1. Clinical effectiveness | 2. Life quality | 3. Immunological function | 4. Complication |
| Qu J.R.56 2012 | 40 | 40 | 64/16 | E:median age 54 years | C:median age 56 years | II, III | — | — | Cinobufotalin injection + TACE (5-FU, IMM, DOX) | TACE (CBP, 5-FU, IMM, DOX) | 28 days | 1. Complication | 2. Comparison of liver function and blood routine examination | 3. Life quality | 4. Solid tumor variation |
| Shen J.57 2009 | 23 | 24 | 36/11 | 52.2 ± 7.4 years old | — | — | — | Cinobufotalin injection + TACE (5-FU, DDP, MMC) | TACE (5-FU, DDP, MMC) | 4 weeks | 1. Clinical effectiveness | 2. Comparison of HIF-1α and VEGF | 3. Life quality | 4. Complication |
| Shen J.58 2015 | 18 | 18 | 23/13 | E:57.5 years old | C:54.7 years old | II, III | — | — | Cinobufotalin injection + TACE (Lobaplatin, DDP) | TACE (Lobaplatin, DDP, MMC) | 2 weeks | 1. Clinical effectiveness | 2. The degree of pain relief | 3. Life quality | 4. Complication |
| Shu X.H.59 2004 | 29 | 29 | 48/10 | Median age: 51 years | — | — | — | Cinobufotalin injection + 5-fluorouracil | 5-fluorouracil | 1–2 rounds (5 days per round) | 1. Clinical effectiveness | 2. The degree of pain relief | 3. Life quality | 4. Complication |
| Su Y.60 2013 | 33 | 30 | 53/10 | E:53.2 ± 8.7 years old | C:52.7 ± 7.9 years old | II, III | — | — | Cinobufotalin injection + TACE (5-FU, HCPT, DOX, MMC) | TACE (5-FU, HCPT, DOX, MMC) | 4 weeks | 1. Clinical effectiveness | 2. Life quality | 3. Complication | 4. Immunological function | 3. Liver function and complication | 1. Clinical effectiveness | 2. QoL scores | 3. Life quality | 4. Survival at 6/12/18/24 months |
| Sun Z.J.61 2002 | 118 | 118 | 197/39 | 51.4 years old | — | — | Cinobufotalin injection + TACE (EPI, MMC, CBP) | TACE (EPI, MMC, CBP) | 2 rounds (4 weeks per round) | 1. Clinical effectiveness | 2. Survival at 12/24/36 months | 3. Immunological function | 4. Liver function and complication | 1. Clinical effectiveness | 2. QoL scores | 3. Life quality | 4. Survival at 6/12/18/24 months |
| Tang J.G.62 1999 | 46 | 42 | 67/21 | E:49 years old | C:48 years old | — | — | — | Cinobufotalin injection + EAM (5-FU, DOX, MMC) | FAM (5-FU, DOX, MMC) | 1 month | 1. Clinical effectiveness | 2. AFP | 3. Life quality | 4. Survival at 6/12/18/24 months |
| Tian X.L.63 2006 | 36 | 36 | 53/19 | E:53.4 ± 10.5 years old | C:52.5 ± 9.6 years old | — | — | — | Cinobufotalin injection + TACE (MMC, DOX, 5-FU, DDP) | TACE (MMC, DOX, 5-FU, DDP) | 2–3 rounds (4–6 weeks per round) | 1. Clinical effectiveness | 2. QoL scores | 3. Life quality | 4. Survival at 6/12/18/24 months |

Continued
| Experimental group | Control group | Sex(M/F) | Age | Disease stage | Child-Pugh scores | KPS score | Treatment group | Control group | Remarks |
|--------------------|---------------|----------|-----|--------------|-------------------|-----------|----------------|---------------|---------|
| Wang C.J. 2001     | 30            | 30       | 48 years old | —    | —               | —         | A, B and C ≥ 30 | Cinobufotalin injection + TACE (DOX, CBP, MMC) | —       | 1. Improvement of clinical symptom |
| Wang L. 2007       | 72            | 70       | 117/25 | E:62.5 years old | C:64.1 years old | — III A and B ≥ 50 | Aidi injection + FAP (5-FU, EPI, DDP) | FAP (5-FU, EPI, DDP) | 2 rounds (30 days per round) | 1. Clinical effectiveness |
| Wang Q.C. 2013     | 24            | 24       | 41/7  | E:median age 55 years | C:median age 57.2 years | — A and B | TACE(MMC, THP, OXA) | — | 3 days | Comparison of T-lymphocyte subsets |
| Wei Y.F. 2015      | 48            | 44       | 61/31 | 58.6±6.8 years old | — A and B | ≥ 70 | Sodium cantharidinate and vitamin B6 + TACE (5-FU, EPI, MMC) | TACE (5-FU, EPI, MMC) | 3 rounds (30 days per round) | 1. Clinical effectiveness |
| Wu H.M. 2006       | 36            | 44       | 69/11 | E:52.4±7.2 years old | C:50.5±8.7 years old | II, III | — | Cinobufotalin injection + TACE (5-FU, MMC, DDP) | TACE (5-FU, MMC, DDP) | 2 rounds (10 days per round) | 1. Clinical effectiveness |
| Wu J.Y. 2006       | 30            | 30       | 53/7  | E:50 years old | C:50 years old | — | — | Cinobufotalin injection + TACE | TACE (HCPT, THP) | 25 days | 1. Clinical effectiveness |
| Wu J.S. 2015       | 15            | 15       | 26-Apr 44-68 years old | — — | — | Sodium cantharidinate and vitamin B6 + TACE | TACE (5-FU, EPI, MMC) | 3 rounds | 1. Comparison of WBC, ALT and AST |
| Wu Z.M. 2010       | 41            | 41       | 50/32 | Median age 45 years old | — — | — | Sodium cantharidinate and vitamin B6 + TACE (5-FU, EPI, DDP) | TACE (5-FU, EPI, DDP) | 2 weeks | 1. Clinical effectiveness |
| Xiao X.S. 2011     | 25            | 25       | 35/15 | E:65.4 years old | C:63.6 years old | — — | — | Cinobufotalin injection + TACE | TACE (MMC, 5-FU, MMC, DDP) | 2 rounds | 1. Numbers of TACE |
| Xie J. 2015        | 50            | 50       | 89/11 | E:58.09±11.67 years old | C:58.32±11.55 years old | — A | — | Scorpion and earthworm + TACE (5-FU, MMC, EPI) | TACE (5-FU, MMC, EPI) | 2 months | 1. Clinical effectiveness |
| Xie Y.F. 2003      | 31            | 31       | 49/13 | Median age 53.5 years | I, II, III | — | — | Jinlong capsule + TACE (5-FU, DDP, MMC) | TACE (5-FU, DDP, MMC) | 21 days | 1. Clinical effectiveness |
| Xu Y.S. 2011       | 64            | 64       | 84/44 | 50.25 years old | — — | — | Sodium noecantharidate (SNCTD) + TACE (DDP, 5-FU, DOX) | TACE (DDP, 5-FU, DOX) | 1–3 rounds (15 days per round) | 1. Clinical effectiveness |

Continued
| Study                         | Experimental group | Control group | Sex(M/F) | Age                | Disease stage | Child-Pugh scores | KPS score | Treatment group                  | Control group | Continued |
|------------------------------|--------------------|---------------|----------|--------------------|---------------|-------------------|-----------|----------------------------------|---------------|-----------|
| Xue Q.76 2010               | 32                 | 30            | 45/17    | E: 45.75 ± 11.40 years old | —             | —                 | > 60      | Cinobufotalin injection + TACE (DDP, 5-FU, DOX) | —             | 1. Clinical effectiveness |
|                              |                    |               |          | C: 45.45 ± 10.70 years old | —             | —                 | —         | TACE (DDP, 5-FU, DOX)           |               | 2. Survival at 6/12/24/36 months |
|                              |                    |               |          |                    |               |                   |           |                                  |               | 3. Comparison of clinical symptoms |
|                              |                    |               |          |                    |               |                   |           |                                  |               | 4. KPS                          |
|                              |                    |               |          |                    |               |                   |           |                                  |               | 5. Complication                    |
| Yang P.Y.77 2013            | 34                 | 36            | 48/22    | 55.1 ± 8.2 years old | A and B       | ≥ 60              | —         | Jinlong capsule + TACE (EPI, 5-FU, DDP) | —             | 1. Clinical effectiveness |
|                              |                    |               |          |                    |               |                   |           | TACE (EPI, 5-FU, DDP)           |               | 2. Comparison of ALT, TBIL and ALB |
|                              |                    |               |          |                    |               |                   |           |                                  |               | 3. KPS scores                    |
|                              |                    |               |          |                    |               |                   |           |                                  |               | 4. TCM clinical symptom           |
|                              |                    |               |          |                    |               |                   |           |                                  |               | 5. TH1 and TH2                    |
|                              |                    |               |          |                    |               |                   |           |                                  |               | 6. Safety analysis                |
| You S.Y.78 2006             | 25                 | 25            | 32/18    | E: 49 ± 3 years old | —             | —                 | —         | Cinobufotalin injection + TACE (5-FU, DDP, EPI) | —             | 1. Clinical effectiveness |
|                              |                    |               |          | C: 48 ± 9 years old | —             | —                 | —         | TACE (5-FU, DDP, EPI)           |               | 2. Survival at 12/24/36 months   |
|                              |                    |               |          |                    |               |                   |           |                                  |               | 3. Complication                   |
| Yu J.G.79 2013              | 30                 | 30            | 29-Nov   | E: 49.7 years old | —             | —                 | > 60      | Cinobufotalin injection + TACE (DDP, DOX, MMC, 5-FU) | —             | 1. Clinical effectiveness |
|                              |                    |               |          | C: 50.8 years old | —             | —                 | —         | TACE (DDP, DOX, MMC, 5-FU)      |               | 2. Clinical symptom improvement  |
|                              |                    |               |          |                    |               |                   |           |                                  |               | 3. Comparison of blood routine examination, liver function and AFP |
| Yuan C.Y.80 2007            | 20                 | 20            | 28-Dec   | E: 52.3 ± 3.5 years old | II, III       | —                 | —         | Cinobufotalin injection + TACE (5-FU, DDP, EPI) | —             | 1. Clinical effectiveness |
|                              |                    |               |          | C: 53.2 ± 3.4 years old | —             | —                 | —         | TACE (5-FU, DDP, EPI)           |               | 2. AFP                           |
|                              |                    |               |          |                    |               |                   |           |                                  |               | 3. Life quality                   |
|                              |                    |               |          |                    |               |                   |           |                                  |               | 4. Immunological function         |
|                              |                    |               |          |                    |               |                   |           |                                  |               | 5. Complication                   |
| Zhang B.81 2007             | 51                 | 49            | 76/24    | E: 54.3 years old | —             | —                 | > 80      | Sodium cantharidinate and vitamin B6 + TACE (THP) | —             | 1. Clinical effectiveness |
|                              |                    |               |          | C: 50.1 years old | —             | —                 | —         | TACE (THP)                       |               | 2. Life quality                   |
|                              |                    |               |          |                    |               |                   |           |                                  |               | 3. Clinical symptom improvement  |
|                              |                    |               |          |                    |               |                   |           |                                  |               | 4. Complication                   |
| Zhang C.Q.82 2005           | 116                | 108           | 187/37   | E: 52.1 ± 9.7 years old | A, B and C    | —                 | —         | Jinlong capsule + TACE (EPI, MMC, CBP) | —             | 1. Survival at 6/12/24/36 months |
|                              |                    |               |          | C: 50.4 ± 8.5 years old | —             | —                 | —         | TACE (EPI, MMC, CBP)            |               | 2. Clinical effectiveness         |
|                              |                    |               |          |                    |               |                   |           |                                  |               | 3. QoL scores                     |
| Zhang M.J.83 2011           | 38                 | 38            | 38/38    | E: 53.99 ± 2.43 years old | —             | —                 | ≥ 60      | Sodium cantharidinate and vitamin B6 + TACE (MMC, DOX) | —             | 1. Clinical effectiveness |
|                              |                    |               |          | C: 55.02 ± 2.16 years old | —             | —                 | —         | TACE (MMC, DOX)                 |               | 2. Clinical symptom improvement and weight |
|                              |                    |               |          |                    |               |                   |           |                                  |               | 3. Life quality                   |
|                              |                    |               |          |                    |               |                   |           |                                  |               | 4. Immunological function         |
|                              |                    |               |          |                    |               |                   |           |                                  |               | 5. Complication                   |
| Zhang T.S.84 2011           | 32                 | 32            | 53/11    | E: 52 years old | —             | —                 | > 60      | Cinobufotalin injection + TACE (DOX, CBP, MMC) | —             | 1. Clinical effectiveness |
|                              |                    |               |          | C: 51 years old | —             | —                 | —         | TACE (DOX, CBP, MMC)            |               | 2. AFP                           |
|                              |                    |               |          |                    |               |                   |           |                                  |               | 3. Complication                   |
|                              |                    |               |          |                    |               |                   |           |                                  |               | 4. Survival at 6/12/24/36 months |

Continued
cisplatin, calcium folinate, gemcitabine, doxorubicin, mitomycin, hydroxycamptothecine and carboplatin. (Table 1) As for the duration of therapy, all included studies except one clearly reported although the range of treating duration was various obviously. All included trials except one clearly introduce the dosage of chemotherapy drugs.

For the included articles, all of them expect 7 studies (12%) were only mentioned the allocation sequence generation without showing the specific random method. However, of the 7 articles, three used shuffling envelopes method and 4 used the random number table method. Only 3 articles (5%) mentioned the allocation concealment from the included studies: the sealed envelope method was the way they chosen. All articles did not report the blinding method, excepted 1 article which was a single-blind randomized clinical trial. Most of studies (92%) were ranked as low risk of outcome integrity data, while 5 articles (8%) reported participants’ dropout reason. None of the articles clearly illustrated the reporting bias and only 2 studies (3%) were rated as low risk for no other bias.

**Meta-analysis.** Objective response rates (CR+PR). Figure 4 illustrated the clinical effects (objective response rate) of traditional insect Chinese medicine in advanced hepatocellular carcinoma (HCC) therapy. There were 46 articles including 3,659 participants analyzed in the forest plot. We conducted subgroup analysis on the condition of the perversive low quality (high bias risk) of included studies. We extracted the high quality articles (5 papers, 510 participants) from the 46 papers based on the Cochrane Collaboration's tools for assessing risk of bias mentioned before. Most of studies (92%) were ranked as low risk of outcome integrity data, while 5 articles (8%) reported participants’ dropout reason. None of the articles clearly illustrated the reporting bias and only 2 studies (3%) were rated as low risk for no other bias.

**Survival time.** Five kinds of survival time were assessed in the meta-analysis including 6 months, 12 months, 18 months, 24 months and 36 months. The meta-analysis showed the 6 months survival time for the experimental group (used traditional insect Chinese medicine combined chemotherapy) and the control group (used chemotherapy alone) was irrelevant \((RR = 1.04, 95\% CI = 0.99 to 1.09, P = 0.14\)) and the heterogeneity was wide ranging \((I^2 = 78\%)\). The heterogeneity was statistically high \((P = 0.14, I^2 = 31\%)\), which might be due to a particular trial included in the meta-analysis. So we performed the sensitivity analysis and if this trial was excluded, the \(I^2\) value would be down to 0%. The fixed effects model was performed to calculate combined data by Mantel-Haenszel test.
| Article names | Random collection method | Allocation concealment | The blinding method | Outcome data integrity | The outcome data of selective report | no other bias sources | The level of bias risk |
|---------------|--------------------------|------------------------|---------------------|-----------------------|-------------------------------------|---------------------|-----------------------|
| Huang W.K. 30 2013 | U                        | U                      | U                   | Y                    | U                                   | U                   | High                  |
| Cao Y. 31 2014  | Y                        | U                      | U                   | Y                    | Y                                   | U                   | Low                   |
| Zeng C.S. 32 2012 | Y                        | U                      | U                   | Y                    | U                                   | Y                   | Low                   |
| Dong M.E. 33 2014 | N                        | U                      | U                   | Y                    | U                                   | U                   | High                  |
| Feng X.M. 34 2012 | U                        | U                      | N                   | Y                    | U                                   | U                   | High                  |
| Fu Z.L. 35 2010  | Y                        | Y                      | U                   | Y                    | U                                   | N                   | Low                   |
| He S.L. 36 2012  | U                        | U                      | U                   | Y                    | Y                                   | U                   | High                  |
| Jia C.H. 37 2008 | N                        | U                      | U                   | Y                    | U                                   | U                   | High                  |
| Jiang C.Y. 38 2013 | U                        | U                      | U                   | Y                    | U                                   | U                   | High                  |
| Ke J. 39 2011    | U                        | U                      | U                   | Y                    | Y                                   | U                   | High                  |
| Kou C.Y. 40 2011 | U                        | U                      | U                   | Y                    | U                                   | U                   | High                  |
| Li R. 41 2013    | U                        | U                      | U                   | Y                    | Y                                   | U                   | High                  |
| Li J. 42 2013    | U                        | U                      | U                   | Y                    | Y                                   | U                   | High                  |
| Li Q. 43 2008    | Y                        | Y                      | U                   | Y                    | U                                   | U                   | Low                   |
| Li Q.M. 44 2003  | U                        | U                      | U                   | Y                    | Y                                   | U                   | High                  |
| Li W.H. 45 2006  | U                        | U                      | N                   | Y                    | U                                   | U                   | High                  |
| Liang B.L. 46 2010 | Y                      | U                      | U                   | Y                    | U                                   | U                   | High                  |
| Liang C.X. 47 2015 | Y                      | U                      | U                   | Y                    | U                                   | U                   | High                  |
| Liang T. 48 2005 | N                        | U                      | U                   | Y                    | Y                                   | U                   | High                  |
| Liang Y. 49 2008 | U                        | U                      | N                   | N                    | U                                   | U                   | High                  |
| Liu X.H. 50 2009 | U                        | U                      | N                   | Y                    | U                                   | U                   | High                  |
| Liu Y.Q. 51 2010 | U                        | U                      | U                   | Y                    | U                                   | U                   | High                  |
| Lu S.J. 52 2014  | U                        | U                      | U                   | Y                    | Y                                   | U                   | High                  |
| Peng W.D. 53 2011 | U                        | U                      | U                   | Y                    | Y                                   | U                   | High                  |
| Qu I.R. 54 2012  | U                        | U                      | U                   | Y                    | Y                                   | U                   | High                  |
| Shen J.J. 55 2009 | U                        | U                      | U                   | Y                    | Y                                   | U                   | High                  |
| Shen J.J. 56 2015 | U                        | U                      | U                   | Y                    | Y                                   | U                   | High                  |
| Shi X.H. 57 2004 | U                        | U                      | U                   | Y                    | Y                                   | U                   | High                  |
| Su Y. 58 2013    | U                        | U                      | U                   | Y                    | Y                                   | U                   | High                  |
| Sun Z. 59 2002   | U                        | U                      | U                   | Y                    | Y                                   | U                   | High                  |
| Tang J.G. 60 1999 | U                        | U                      | U                   | Y                    | Y                                   | U                   | High                  |
| Tian X.L. 61 2006 | U                        | U                      | U                   | N                    | U                                   | U                   | High                  |
| Wang C. 62 2001  | U                        | U                      | U                   | Y                    | Y                                   | U                   | High                  |
| Wang L. 63 2007  | U                        | U                      | N                   | Y                    | U                                   | U                   | High                  |
| Wang Q.C. 64 2013 | U                        | U                      | U                   | Y                    | Y                                   | U                   | High                  |
| Wei Y.F. 65 2015  | U                        | U                      | U                   | Y                    | N                                   | U                   | High                  |
| Wu H.M. 66 2000  | U                        | U                      | U                   | Y                    | Y                                   | U                   | High                  |
| Wu I.Y. 67 2006  | U                        | U                      | U                   | Y                    | Y                                   | U                   | High                  |
| Wu J.S. 68 2015  | U                        | U                      | U                   | Y                    | U                                   | U                   | High                  |
| Wu Z.M. 69 2010  | U                        | U                      | U                   | Y                    | Y                                   | U                   | High                  |
| Xiao X.S. 70 2011 | N                        | U                      | N                   | Y                    | U                                   | U                   | High                  |
| Xie J. 71 2015   | U                        | U                      | N                   | Y                    | U                                   | U                   | High                  |
| Xie Y.F. 72 2003 | Y                        | Y                      | U                   | Y                    | Y                                   | U                   | Low                   |
| Xu Y.S. 73 2011  | U                        | U                      | U                   | Y                    | Y                                   | U                   | High                  |
| Xue Q. 74 2010   | U                        | U                      | U                   | Y                    | Y                                   | U                   | High                  |
| Yang P.Y. 75 2013 | U                        | U                      | U                   | Y                    | Y                                   | U                   | High                  |
| You S.Y. 76 2006 | U                        | U                      | N                   | Y                    | U                                   | U                   | High                  |
| Yu J.G. 77 2013  | U                        | U                      | U                   | Y                    | Y                                   | U                   | High                  |
| Yuan C.Y. 78 2007 | U                        | U                      | U                   | Y                    | Y                                   | U                   | High                  |
| Zhang B. 79 2007 | U                        | U                      | U                   | Y                    | Y                                   | U                   | High                  |
| Zhang C.Q. 80 2005 | U                      | U                      | U                   | Y                    | N                                   | U                   | High                  |
| Zhang M.J. 81 2011 | U                        | U                      | U                   | Y                    | Y                                   | U                   | High                  |
| Zhang T.S. 82 2011 | U                        | U                      | U                   | N                    | U                                   | U                   | High                  |
| Zhu W.O. 83 2014 | U                        | U                      | U                   | Y                    | Y                                   | U                   | High                  |
| Deng Z.Y. 84 2015 | U                        | U                      | U                   | Y                    | Y                                   | U                   | High                  |
| Zhou J.S. 85 2006 | U                        | U                      | U                   | Y                    | Y                                   | U                   | High                  |

**Table 2.** The Risk Bias Evaluation of Articles Note: Y refers to “yeas”; N refers to “no”; U refers to “unclear”.
model was performed to pool data. Only four articles including 289 participants analyzed the 18 months survival time\cite{51, 63, 71, 85}. The meta-analysis illustrated the experimental group significantly improved the 18 months survival time compared with the control group (RR = 2.62, 95% CI = 1.70 to 4.05, \(P < 0.001\)). There was no heterogeneity in these four articles (\(P = 0.44, I^2 = 0\%\)), so the fixed effects model was performed to pool data. Nineteen articles including 1,825 participants analyzed the 24 months survival time\cite{38, 42, 44, 45, 47, 50, 52, 54, 61, 63, 64, 67, 71, 75, 76, 78, 82, 84, 85}. The meta-analysis illustrated the experimental group significantly improved the 24 months survival time compared with the control group (RR = 1.70, 95% CI = 1.50 to 1.91, \(P < 0.001\)). The heterogeneity was low among the included articles (\(P = 0.24, I^2 = 17\%\)) and the fixed effects model was performed to pool data. Twelve articles including 1,381 participants analyzed the 36 months survival time\cite{42, 44, 52, 61, 64, 67, 75, 76, 78, 82, 84}. The meta-analysis illustrated the experimental group significantly improved the 36 months survival time compared with the control group (RR = 1.93, 95% CI = 1.55 to 2.39, \(P < 0.001\)). We did not find any valid articles that had analyzed the 5 years survival time, and only one article analyzed 3 months survival time\cite{68}.

**Indexes improvement for QoL scores, KPS, and AFP.** Eighteen trials including 1,337 patients reported data on quality of life (QoL) scores improvement\cite{31, 35, 38, 42, 45, 51, 54, 55, 59, 60, 63, 65, 76, 80, 81, 83, 85}. No obvious heterogeneity was found in the included articles (\(P = 0.22, I^2 = 19\%\)), so that the fixed effects model was conducted to pool data. The meta-analysis showed that the QoL scores improvement in the experimental group was superior to the control group (RR = 1.74, 95% CI = 1.53 to 1.97, \(P < 0.001\)). Only 4 trials including 318 patients reported data on Karnofsky performance scores (KPS) improvement\cite{33, 36, 37, 74, 9}, and 9 trials including 608 patients on AFP improvement\cite{32, 33, 62, 65, 68, 78–80, 84}. Both heterogeneities of the two indexes were not notable (KPS: \(P = 0.56, I^2 = 0\%\); AFP: \(P = 0.35, I^2 = 11\%\)) and the statistical model was fixed effects model. The meta-analysis showed both the two indexes (KPS and AFP) were significantly improved in experimental group compared with the control group (KPS: RR = 1.84, 95% CI = 1.42 to 2.39, \(P < 0.001\); AFP: RR = 1.57, 95% CI = 1.32 to 1.87, \(P < 0.001\)). (Fig. 6).

**Side effects.** This part of meta-analysis included 6 kinds of side effects, which contained bone marrow depression, gastrointestinal adverse reactions, liver damage, kidney damage, fever and pain. As for bone marrow depression, two laboratory indexes including white blood cell (WBC) decrease (13 articles, 1058 patients)\cite{30, 32, 37, 40, 43, 46, 51, 53, 63–65, 67, 68} and hemoglobin (HB) decrease (7 articles, 563 patients)\cite{30–32, 37, 53, 64, 67, 78–80} were applied as random effects model (the heterogeneity of WBC decrease: \(P < 0.001, I^2 = 85\%\); HB decrease: \(P = 0.04, I^2 = 54\%\)); one laboratory index named the platelets (PLT) decrease (only 3 articles, 193 patients)\cite{32, 37, 53} was applied fixed effects model (heterogeneity: \(P = 0.6, I^2 = 0\%\)). The subgroup analysis (seen in the Supplementary Information of the article) of WBC decrease was performed based on the drugs classification, literature publication years and experimental areas, but the source of heterogeneity was still unclear. However, the subgroup analysis of HB decrease found that the heterogeneity came from experimental areas (North of China: \(P = 0.27, I^2 = 23\%\); South of China: \(P = 0.13, I^2 = 46\%\)). The incidence rates of HB decrease and PLT decrease in experimental group were irrelevant to control group.
with corresponding Risk Ratio (RR) and 95% CI were (0.84, 0.62 to 1.12, \( P = 0.23 \)) and (0.97, 0.75 to 1.26, \( P = 0.84 \)), respectively. The incidence rate of WBC decrease in the experiment group was lower than in control: (0.74, 0.55 to 0.99, \( P = 0.04 \)). (Fig. 7). Red blood cell (RBC) decrease, another important component of bone marrow depression, was excluded owing to only one trial analyzing it.30.
Twenty articles including 1,529 patients reported data on gastrointestinal adverse reactions. The random effects model was conducted to pool data because the heterogeneity ($P < 0.001$, $I^2 = 62\%$) was obvious. We made the subgroup analysis based on the drugs categories, publication years and experimental areas. The outcome of subgroup analysis showed that the variation among the different experimental areas was the source of heterogeneity (North of China: $P = 0.34$, $I^2 = 11\%$; South of China: $P = 0.18$, $I^2 = 28\%$).

The meta-analysis showed the gastrointestinal adverse reactions in the experimental group were significantly fewer than the control group ($RR = 0.63$, 95% CI = 0.51 to 0.77, $P < 0.001$).

Figure 5. The forest plot of survival time for traditional insect Chinese medicine and the related preparation combined chemotherapy versus chemotherapy alone (M-H: Mantel-Haenszel estimates; CI: Confidence Interval).
Eleven articles including 815 patients and 5 articles including 340 participants gathered information on liver damage\textsuperscript{33, 34, 40, 51, 53, 67, 73, 78, 80, 81, 83} and kidney damage\textsuperscript{53, 67, 78, 80, 83} respectively. The random effects model was performed to collect data for the liver damage group because the heterogeneity was high ($P < 0.001$, $I^2 = 92\%$). The subgroup analysis based on the drugs categories, publication years and experimental areas didn't reveal the source of heterogeneity. The fixed effects model was conducted to collect data for kidney damage group because no obvious heterogeneity was found in the included articles ($P = 0.97$, $I^2 = 0\%$). We also didn't find the source of heterogeneity through the subgroup analysis. The meta-analysis also showed both these two indexes in the treatment group and the control group were irrelevant (liver damage: $RR = 0.56$, 95\% CI $= 0.31$ to $1.02$, $P = 0.06 > 0.05$; kidney damage: $RR = 0.55$, 95\% CI $= 0.24$ to $1.27$, $P = 0.16 > 0.05$).

Ten articles including 621 patients\textsuperscript{30, 37, 46, 51, 53, 64, 67, 70, 87} and eight articles including 490 patients\textsuperscript{30, 37, 42, 53, 64, 67, 70, 87} reported fever and pain respectively. They all used the random effects model for the reason of the obvious heterogeneity ($P < 0.001$, $I^2 = 72\%$; $P < 0.001$, $I^2 = 80\%$). We also didn't find the source of heterogeneity through the subgroup analysis. The meta-analysis also showed both these two indexes in the treatment group and the control group.

---

**Figure 6.** The forest plot of QoL scores, KPS and AFP improvement for traditional insect Chinese medicine and the related preparation combined chemotherapy versus chemotherapy alone (QoL: Quality of life; KPS: Karnofsky performance scores; AFP: Alpha fetoprotein; $M-H$: Mantel-Haenszel estimates; CI: Confidence Interval).
control group were irrelevant (RR = 0.82, 95% CI = 0.58 to 1.15, P > 0.05; RR = 0.82, 95% CI = 0.53 to 1.29, P = 0.40 > 0.05). (Fig. 8).

**Immune function.** Immune function after tumor therapy was measured by continuous laboratory data as follows: CD3+, CD4+, CD8+, CD4+/CD8+ and Natural Killer cell (NK). As the difference of standard deviation (SD) in the same article laboratory indexes was obvious, Standard Mean Difference (Std.MD) was conducted as combined statistics. Significant improvement of CD3+ (7 studies, 662 patients)\(^{38, 45, 52, 55, 61, 80, 83}\), CD4+ (7 studies, 659 patients)\(^{38, 45, 52, 55, 61, 80, 83}\), CD4+/CD8+ (8 studies, 721 patients)\(^{38, 45, 52, 55, 74, 80, 83}\) and NK (6 studies, 565 patients)\(^{38, 45, 52, 55, 61, 74, 80, 83}\) in the experimental group were found in the forest plot compared with the control group with associated Std.MD (95% CI) were 1.55 (1.01 to 2.08, P < 0.001), 2.49 (1.34 to 3.64, P < 0.001), 1.70 (0.69 2.70, P < 0.001) and 1.79 (0.49 to 3.09, P = 0.007). But CD8+ (3 studies, 240 patients)\(^{38, 45, 55, 83}\) in the experimental group was irrelevant to control group with associated Std.MD (95% CI) was 0.93 (−0.66 to 2.52, P = 0.25 > 0.05). All heterogeneity that was high (P < 0.001, I² = 88%; P < 0.001, I² = 97%; P < 0.001, I² = 97%; P < 0.001, I² = 97%) might be attributed to the differences in the measurement time, measurement areas or the ingredient of traditional insect Chinese medicine. The random effects models were conducted to pool data and so any conclusions need to be made with caution (Fig. 9).

**Figure 7.** The forest plots of bone marrow depression (WBC decrease, HB decrease and PLT decrease) for traditional insect Chinese medicine and the related preparation combined chemotherapy versus chemotherapy alone (PLT: Platelets, WBC: White blood cell, HB: Hemoglobin, M-H: Mantel-Haenszel estimates; CI: Confidence Interval).
Network contribution graphs of included studies. Figure 10 was the network contribution graph of the experimental group and the control group. This figure illustrated the treating method numbers in orders: cinobufotalin injection plus TACE versus TACE contained 26 studies, sodium cantharidinate vitamin B6 injection plus TACE versus TACE contained 7 studies, Jinlong capsule plus TACE versus TACE contained 6 studies, and both Aidi injection plus TACE and sodium demethylcantharidate (SNCTD) plus TACE versus TACE contained 1 study, respectively. Five treating methods contributed 20% respectively to the entire network graph.

Figure 8. The forest plots of other side effects (gastrointestinal adverse reaction, liver damage, fever, pain and kidney damage) for traditional insect Chinese medicine and the related preparation combined chemotherapy versus chemotherapy alone (M-H: Mantel-Haenszel estimates; CI: Confidence Interval).
Funnel plot characteristics. We applied the pooled odds ratio (OR) as the midpoint to draw the funnel plot (Fig. 11). The publication bias was evaluated in the funnel plot by comparing the symmetry of included studies on objective response rate. The funnel plot was symmetrical in visual while the images (Fig. 12) and calculating results of Egger’s test \( (t = -2.96, P = 0.005) \) and Begg’s test \( (z = 1.96, P = 0.092) \) indicated the potential publication bias did exist.

**Discussion**

Hepatocellular carcinoma (HCC) is a worldwide serious disease, causing serious health problems to human beings. The treating methods of western medicine, which include liver transplantation, liver resection, radiofrequency ablation (RFA), transcatheter hepatic arterial chemoembolization (TACE) and molecular targeted drugs, have already been used on HCC therapy for a long time. As for non-surgical hepatocellular carcinoma, the effective clinical evidence is insufficient and the heated debate also was aroused for the selection of optimal treating methods. The current chemotherapy performed to end-stage HCC has been proved many side effects: bone...
Figure 10. Network Contribution Graph: as for A vs B, for example, the contribute proportion of “A vs B” for “A vs B” is 100%, and for “A vs C”, “A vs D”, “A vs E” and “A vs F” was 50% respectively. The contribute proportion for entire network was 20% and 26 clinical studies included. Note: (A) cinobufotalin injection + TACE; (B) TACE; (C) Jinlong capsule + TACE; (D) Aidi injection + TACE; (E) Sodium Cantharidinate and Vitamin B6 Injection + TACE; F: Sodium Demethylcantharidate (SNCTD) + TACE.

Figure 11. The funnel plot of objective response rate (CR+PR) Note: CR: Complete response rate. PR: Partial response rate.

Figure 12. The Egger’s and Begg’s test of objective response rate (CR+PR).
marrow depression, gastrointestinal adverse reactions, liver damage, kidney damage, fever, pain, hair loss, dizziness, et al. These complications also become a huge burden for HCC patients. Based on this serious context, various complementary and alternative medicine (CAM) treatments have been administered for HCC in clinical practice. The traditional insect Chinese medicine, as an essential part of TCM, has been utilized to treat HCC as an auxiliary method (or CAM methods) for a long time. The effective and safe evaluation of traditional insect Chinese medicine for non-surgical HCC treatment is urgent and necessary. To the best of our knowledge, this article is the first PRISMA compliant systemic reviews and meta-analysis to evaluate the effects and safety of traditional insect Chinese medicine combined chemotherapy for non-surgical HCC. Fifty-seven articles, all of which were conducted in China, included 4,651 participants in the meta-analysis. Even with strong cultural and population bias, seven obvious advantages still need to be emphasized: (a) fourteen medical databases were utilized and the publication language was English, Chinese and Japanese; (b) the article quality was strictly accessed and evaluated by three cooperated reviewers (T.B. Song, Y. Wan and L. Shang); (c) we performed a comprehensive analysis for different categories of the included traditional insect Chinese medicine and the subgroup analysis and sensitivity analysis was both well conducted to seek the source of heterogeneity; (d) we contacted authors on whether the included articles could receive on full-text; (e) Egger’s test, Begg’s test and funnel plot was performed to confirm whether the publication bias existed in the studies; (f) the contribution network plot graph was strictly designed to evaluate the mutual effectiveness among the included traditional insect Chinese medicines as clearly exhibited as graphs; (g) the Cochrane risk of bias tool was performed to assess the study quality. The studies’ outcomes showed good qualities were still insufficient for the reason of the high risk on blinding methods bias, selective reporting bias, and other bias.

The meta-analysis was carried out in 46 articles to evaluate the objective response rate (CR + PR), showing the significantly effectiveness in the experimental group (traditional insect Chinese medicine combined chemotherapy) compared with the control group (chemotherapy) alone. The subgroup analysis based on the article’s quality difference also provided the same result. These results suggest that the short-term effects of traditional insect Chinese medicine as auxiliary method combined chemotherapy are superior to chemotherapy alone. It is important to note that the publication bias on objective response rate indicates inconformity between funnel plot in visual appearance and Egger’s/Begg’s test results. Involved studies showed that experimental groups significantly improve the survival time at 12 months, 18 months, 24 months and 36 months compared with control groups, revealing that traditional insect Chinese medicine combined chemotherapy might prolong the survival time of non-surgical HCC patients. However, no statistical difference was found in 6 months survival time. The meta-analysis contained quality of life (QoL) scores, Karnofsky performance scores (KPS) and AFP improvement, all showing significant improvement in the experimental group compared with the control group. We did not observe large heterogeneity among these studies and the results indicated an excellent improvement of patients’ life quality for the utilization of traditional insect Chinese medicine. The meta-analysis evaluated the side effects ratio after therapy, clearly showing the obvious reduction of gastrointestinal adverse reaction and WBC decrease in the experimental group compared to the control group. The liver damage, kidney damage, fever, pain, HB decrease and PLT decrease did not show significantly statistically difference although all of them indicated the same conclusion that side effects ratio of traditional insect Chinese medicine combined chemotherapy lower than chemotherapy alone. Although we found that the obvious heterogeneity in WBC decrease, HB decrease, gastrointestinal adverse reactions, liver damage, fever and pain was obvious, most of them did not show the source of heterogeneity except the HB decrease and gastrointestinal adverse reactions. The heterogeneity of HB decrease and gastrointestinal adverse reactions both came from the variation among the different experimental areas. The meta-analysis showed that the improvement of immune function in the experimental group was higher than the control group although the heterogeneity was obvious. We did not find the source of heterogeneity of them. So we could not give the firmly conclusion on the effectiveness of immune function improvement except we could include more relevant articles in the future meta-analysis. For forty-six included trials focused on objective response ratio, all experimental groups utilized traditional insect Chinese medicine related preparation as auxiliary therapy combined chemotherapy for the advanced HCC therapy.

The included traditional insect Chinese medical preparations contained cinobufotalin injection (28 trials, 62%), Jinfalong capsule (6 trials, 13%), sodium cantharidinate and vitamin B6 injection (7 trials, 15%), Aidi injection (1 trial, 2%), sodium demethylcantharidate (SNCTD) (1 trial, 2%), compound cantharis capsule (1 trial, 2%), Aiyishi injection (1 trial, 2%) and Qining injection (1 trial, 2%). It has been clearly revealed that the cinobufotalin injection contributes as the major adjuvant therapy choice for non-surgical HCC. Transcatheter hepatic arterial chemoembolization (TACE) was ranked as the most frequently way of chemotherapy both in experimental groups and control groups (43 trials, 93%). Chemotherapy drugs, applied in HCC patients’ therapy through the way of TACE with 1-4 of them, were diversified, such as OXA (oxaliplatin), DDP (cisplatin), CBP (carboplatin), lobaplatin, EPI (epirubicin), DOX (doxorubicin), THP (pirarubicin), MMC (mitomycin) and HCPT (hydroxy-camptothecine). The dosage of traditional insect Chinese medicine and chemotherapy drugs had their own differences.

The publication bias for objective response rate did exist in this meta-analysis after Egger’s and Begg’s test. It might be derived from (a) some authors tended to deliver positive results of articles to editors while prejudiced negative results; (b) some magazine editors or reviewers had a preference to positive results of articles while caviled to negative results to some extent; (c) trials that received government funding had more possibility to publish on some magazines than received private or company funding. The meta-analysis would overstate the degree of association between treating effects and risk factors because of the publication bias, which would bring mistakes for clinical patient’s therapy or health decision-making.
Limitation. There are several potential limitations of current data and results that should be interpreted with caution. Firstly, included clinical studies all conducted in different centers in China, which may bring the regional and cultural bias and influence the widely application of traditional insect Chinese medicine in the future. Secondly, for the reason of varied medical development in different regions of China, clinical centers in China conducting the trials have different clinical levels of tumor diagnosis and treatment, which could result in a bias of the reported incidence rate. Thirdly, the included randomized clinical trials have many flaws caused by human baseline risk factors (all patients were Chinese), incomplete methodological design of trials, small sample trials (some studies have less than 30 patients per group) and index criteria deficiency (the information of the clinical stage of HCC or Child-Pugh scores deficiency). Fourthly, some results showed significantly heterogeneity among the included studies, which may be due to the sample size, different experimental region in China, medicine application and dose, publication years, as well as duration of treatment. However, we need to understand that establishing the random-effects model to pool data cannot give exact and stable conclusion in this situation. Fifthly, the application of traditional insect Chinese medical preparations varied in included articles. For example, some insect medical preparations were used through the way of injection (i.e. cinobufotalin injection, sodium cantharidinate and vitamin B6 injection, Aidi injection, et al.) and some were administrated through the oral way (i.e. Jinlong capsule, compound cantharis capsule, et al.). The time of applying medicines was unsynchronized, which also might exert potential time bias.

Conclusion This system review and meta-analysis offers a practical and beneficial result for the effectiveness and safety of traditional insect Chinese medicine combined chemotherapy on non-surgical hepatocellular carcinoma (HCC). This combined therapy can provide assistance for improving the objective response rate (CR + PR) of HCC, prolonging long term survival time (12, 18, 24, 36 months), enhancing life quality (QoL scores and KPS) of patients, increasing some laboratory index (AFP) and immune functions (CD3+, CD4+, CD4+/CD8+, NK) and reducing some adverse effects (WBC decrease, gastrointestinal adverse effects). However, some results (6 months survival time, PLT decrease, HB decrease, liver damage, kidney damage, pain, fever and CD8+) cannot support a convincing conclusion because they cannot obtain the statistical difference. We should make the conclusion cautiously that this combined therapy can be applied as an auxiliary clinical treating method on non-surgical HCC treatment because many included publications' low quality increases risk and bias and affects the reliability of study to some extent. So the traditional insect Chinese medicine and related preparation still need further standard, multicenter, double-blind randomized clinical trials (RCTs) to provide more clinical evidences in the future.

Data Availability Statement. All data in this article are fully available without restriction.

References
1. Ferlay, J., Shin, H. R., Bray, F. & Forman, D. et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. *International Journal of Cancer.*, 127, 2893–2917 (2010).
2. WHO. World Health Organization Mortality Database http://apps.who.int/healthinfo/statistics/mortality/whodims/psms/ (2015) (2015).
3. Zarn, A., Bray, F., Cente, M. M. & Ferlay, J. et al. Global cancer statistics. 2008. *CA: A Cancer Journal for Clinicians.*, 61, 69–90 (2011).
4. Torre, L. A., Bray, F. & Siegel, R. L. et al. Global cancer statistics, 2012. *CA: A Cancer Journal for Clinicians.* 60, 11–13 (2015).
5. siegel, R., Ward, E., Brawley, O. & Jemal, A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. *CA: A Cancer Journal for Clinicians.*, 61, 212–236 (2011).
6. Maluccio, M. & Covey, A. Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. *CA: A Cancer Journal for Clinicians.* 62(no. 6), 394–399 (2012).
7. Alazawi, W., Cunningham, M., Dearden, J. & Foster, G. R. Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection. *Alimentary Pharmacology & Therapeutics.* 32, 344–355 (2010).
8. Bosch, F. X., Ribes, J., Diaz, M. & Clíries, R. Primary liver cancer: world-wide incidence and trends. *Gastroenterology.* 127, 5–16 (2004).
9. Jordi, B., Maria, R. & Morris, S. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. *Gastroenterology.* 130, 855–853 (2016).
10. Alejandro, E., Josep, M. L. & Jordi, B. Hepatocellular carcinoma. *Lancet.* 379, 1245–1246 (2012).
11. El-Serag, H. B. Hepatocellular carcinoma. *The New England Journal of Medicine.* 365, 1118–1127 (2011).
12. Andres, P., Michael, M. & Joachim, D. Liver cancer:targeted future options. *World Journal of Hepatology.* 3, 34–44 (2011).
13. Gao, X. Prospects and research situation of insect-drugs. *China Journal of Traditional Chinese Medicine and Pharmacy.* 25, 807–809 (2010).
14. Yan, J. M. The Annotation of Fifty-two patients side (ed. Wu, B. Y.) 251–257 (*TCM Ancient Books Publishing House* 2005).
15. Gu, G. G. Shenmeng’s herbal classic (ed. Chen, H.) 11–303 (*The Academy Press House* 2007).
16. Zhe, L. C. The application of insects-drugs (ed. Zhang, K.) 13–564 (*People's Health Publishing House* 2016).
17. Zeng, C. S., Cai, M. L. & Li, J. W. et al. Clinical observation of 16 patients with primary liver cancer treated by TACE with continuous infusing Huachansu injection in portal vein. *China Journal of Clinical Medicine and Pharmacy.* 39, 792–794 (2010).
18. Xu, Y. S., Meng, Q. S. & Su, F. et al. Clinical study of sodium norcantharidin combined with transcathether hepatic arterial chemoembolization as treatment for advanced liver cancer. *Medical Recapitulate.* 17, 2058–2059 (2011).
19. Mother, D., Liberati, A. & Tetzlaff, J. et al. Preferred reporting items for systematic reviews and meta-analysis: the PRISMA statement. *British Medical Journal.* 339, 2335 (2009).
20. NCCN. The NCCN hepatobiliary cancer clinical practice guidelines in oncology (version 3, 2015) https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf (NCCN 2015).
21. Reig, M., Darnell, A. & Forner, A. et al. Systemic therapy for hepatocellular carcinoma: the issue of treatment stage migration and registration of progression using the BCLC-refined RECIST. *Seminars Liver Disease.* 34, 444–455 (2014).
22. Higgins, J. P. T. & Green, S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. *The Cochrane Collaboration,* http://handbook.cochrane.org (2011).
Huang, W. K., Liu, D. Y. & You, L. et al. Jilong capsule decreases adverse reactions after transcatheter arterial chemoembolization (TACE) in patients with hepatocellular carcinoma. Oncology and Translational Medicine. 1, 87–91 (2015).

Cao, Y. Efficacy and safety of compound cantharis capsules in treatment of primary liver cancer and cost-effectiveness evaluation. Evaluation and Analysis of Drug-use in Hospitals of China. 14, 711–713 (2014).

Zeng, C. S., Cai, L. M. & Li, J. W. et al. Influence of Jilong capsule combined with transarterial chemoembolization on quality of life of patients with primary liver cancer. Chinese Journal of Clinical Oncology. 39, 1839–1842 (2012).

Deng, Z. Y. & Duan, H. R. Clinical observation of Cinobufacini injection combined with TACE in the treatment of hepatocellular carcinoma. Tianjin Journal of Traditional Chinese Medicine. 32, 275–278 (2015).

Dong, M. E. The clinical observation of Huachansu injection in combination with small dose of arterial perfusion chemotherapy treatment in middle and advanced stages of hepatocellular carcinoma. Journal of Emergency in Traditional Chinese Medicine. 32, 350–351 (2014).

Feng, X. M., Fu, F. X. & Han, W. Q. et al. The clinical observation of FOLFOX4 program combined with Huachansu injection for 52 cases middle and advanced stages of hepatocellular carcinoma. Journal of Chinese Community Physicians. 14, 78–79 (2012).

Fu, Z. L., Qu, Z. H. & Wang, Y. The clinical research of Huachansu injection combined with interventional therapy for middle and advanced stages of hepatocellular carcinoma. China Practical Medical. 5, 107–108 (2010).

He, S. L., Liu, L. M. & Sun, X. J. et al. Effect of huachansu injection sequence TACE including oxaliplatin regimen for advanced hepatocellular carcinoma. Chinese Journal of Clinicians (Electronic Edition). 6, 3880–3883 (2012).

Ji, J. F., Deng, X. L. & Xiao, Q. J. et al. Percutaneous cinobufotalin injection under ultrasonography combined with transcatheter arterial chemoembolization on treating portal vein tumor thrombus. Journal of Changzhou University of Chinese Medicine. 31, 1059–1062 (2015).

Jia, C. H., Wang, W. Y. & Kang, Y. Clinical studies on combination therapy of jilong capsule and transarterial chemoembolization in treatment of primary hepatic carcinoma. Chinese Journal of Cancer Prevention and Treatment. 15, 1416–1418 (2008).

Jiang, C. Y., Cao, J. J. & Cheng, Q. The clinical evaluation of Jilong capsule combines with transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma. Medical Innovation of China. 10, 110–111 (2013).

Ke, J., Lu, K. & Li, Y. Clinical observation of patients with primary liver cancer treated by Cinobufagin injection combined with transcatheter arterial chemoembolization (TACE). China Practical Medical. 6, 1–2 (2011).

Kou, C. X. & Xu, Z. The clinical analysis of Huachansu injection combined with transcatheter arterial chemoembolization for middle and advanced stages of hepatocellular carcinoma treatment. Chinese Journal of Mis-diagnoses. 11, 6151–6152 (2011).

Li, B., Zhao, L. X. & Liu, Z. W. et al. Jilong capsule combined with interventional therapy for primary hepatocellular carcinomas: a clinical analysis on 150 patients. Chinese Journal of Hepatobiliary Surgery. 19, 530–533 (2013).

Li, J. & Qi, C. H. Clinical efficacy of transcatheter arterial chemoembolization combined Traditional Chinese Medicine for the treatment of primary liver cancer. Chinese Imaging Journal of Integrated Traditional and Western Medicine. 11, 627–629 (2013).

Li, Q., Sun, B. M. & Peng, Y. H. et al. Clinical Study on the Treatment of Primary Liver Cancer by Cinobufotain Combined with Transcatheter Arterial Chemoembolization. Acta Universitatis Traditionis Medicalis Sinensis Pharmacologicae Shanghai. 22, 32–34 (2008).

Li, Q. M. & Zhao, Y. L. The clinical observation of Qining injection combined interventional therapy for hepatocellular carcinoma. Journal of Cancer Control. 16, 160–161 (2003).

Li, W. H., Yin, J. P. & Wang, X. H. The clinical observation of Huachansu injection combined interventional therapy for middle and advanced stages of hepatocellular carcinoma. World clinical drugs. 27, 304–306 (2006).

Li, H., Lai, N. M. & Liu, S. M. et al. The influence of Cantharis acid sodium vitamin B6 for liver function and blood picture of hepatocellular carcinoma artery Perfusion chemotherapy embolism. Chinese Medicine. 5, 701–702 (2010).

Liang, C. X. The clinical observation of Cantharis acid sodium injection combined interventional therapy for hepatocellular carcinoma. Chinese Journal of Clinical Research. 28, 742–744 (2015).

Li, T. J., Qin, C. Y. & Zhang, C. Q. et al. Clinical studies on the combination therapy with Jilong capsule and chemotherapy plus embolization by hepatic artery catheterization on primary hepatocellular carcinoma. Chinese Journal of Clinical Oncology. 32, 641–643 (2005).

Liang, Y., Long, J. Z. & Liu, H. et al. Study of cinobufotalin and interferon combined with transcatheter hepatic arterial chemoembolization on primary hepatocellular carcinoma. Modern Journal of Integrated Traditional Chinese and Western Medicine. 17, 1628–1630 (2008).

Liu, X. H., Fu, H. & Zhu, Q. H. et al. The clinical study of cinobufotalin injection combined with transcatheter hepatic arterial chemoembolization on hepatocellular carcinoma. Chinese Journal of Modern Drug Application. 3, 134–135 (2009).

Liu, Y. Q., Yu, Z. H. & Shao, Z. H. et al. The clinical study of cinobufotalin injection combined with transcatheter arterial chemoembolization for hepatocellular carcinoma treatment. Chinese Rural Health Service Administration. 30, 402–404 (2010).

Liu, S. J. Thirty cases of patients with advanced liver cancer treated with TCM syndrome differentiation combined with cinobufotalin injection. Henan traditional Chinese Medicine. 34, 2348–2349 (2012).

Peng, W. D. The clinical observation of compound cantharis capsule combined with chemotherapy for advanced primary hepatocellular carcinoma treatment. Guiding Journal of Traditional Chinese Medicine Pharmacy. 17, 39–40 (2011).

Qu, J. R., Wang, Q. S. & Dai, J. et al. The preventive effect for adverse effect of Secretio bufoxin injection on primary hepatocellular carcinoma after intervention. Chinese Journal of Difficult and Complicated Cases. 11, 294–295 (2012).

Shen, J. J. The clinical effect of cinobufotalin injection by transcatheter arterial chemoembolization combined with intravenous on treating primary liver cancer. Chinese Journal of Clinical Hepatology. 25, 207–209 (2009).

Shen, J. J. & Tan, S. Z. The clinical study of cinobufotalin injection combined with transarterial arterial chemoembolization for advance hepatocellular carcinoma treatment. Jilin Journal of Traditional Chinese Medicine. 35, 678–680 (2015).

Shu, X. H. & Tan, B. X. The short term clinical observation of cinobufotalin injection combined with 5-fluorouracil for advanced hepatocellular carcinoma treatment. The Journal of Sichuan oncology prevention. 17, 88–89 (2004).

Sun, Y., Yang, J. Q. & Guo, C. Q. The cinobufotalin injection in combination with transcatheter arterial chemoembolization for advance hepatocellular carcinoma treatment. Journal of Basic and Clinical Oncology. 26, 245–246 (2013).

Sun, Z. J. & Pan, C. E. & Wang, G. J. The clinical study by cinobufotalin injection in combination with transcatheter arterial chemoembolization. Cancer Research on Prevention and Treatment. 29, 67–68 (2002).
62. Tang, J. G., Wei, Z. X., Yin, J. F. & Guan, L. R. 46 cases of end-stage hepatocellular carcinoma treatment by cinobufotalin injection in combination with transcatheter arterial chemoembozilation. *Chinese Journal of Integrated Traditional and Western Medicine on Liver Disease*, 9, 54 (1999).

63. Tian, X. L. The clinical effects analysis of Aiyishu injection combined with interventional therapy on 36 cases advanced hepatocellular carcinoma therapy. *Central Plains Medical Journal*, 33, 32–34 (2006).

64. Wang, C. J., Chen, Q. Q. & Deng, L. et al. Hepatic artery infusion of cinobufotalin for treating advanced hepatocellular carcinoma. *Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases*, 11, 5–7 (2001).

65. Wang, L. J., Li, X. D., Ma, M. & Zhang, H. Z. Efficacy of Banmao complex injection in chemotherapy of primary hepatcic carcinoma. *Modern Oncology*, 15, 1812–1813 (2007).

66. Wang, Q. C., Chen, W. & Chen, D. Q. et al. Influence of toad venom, salvia miltiorrhiza and matrine combined with transcatheter arterial chemoembozilation on the immune function of the patients with hepatocellular carcinoma. *Chinese Journal of Gastroenterology and Hepatology*, 22, 632–634 (2013).

67. Wei, Y. F., Wu, J. S. & Hoo, Z. G. et al. The clinical evaluation of disodium cantharidinate and vitamin B6 injection combined with interventional embozilation chemotherapy for 48 cases end-stage hepatocellular carcinoma. *China Pharmaceuticals*, 24, 72–74 (2015).

68. Wu, H. M., Zhu, Z. D., Ling, C. Q. & Chen, Z. The clinical observation for hepatocellular carcinoma treatment by cinobufotalin combined interventional embozilation chemotherapy. *Liaoning Journal of Traditional Chinese Medicine*, 27, 127–128 (2000).

69. Wu, J. Y. Clinical observation for interventional embozilation chemotherapy by arterial infusion of cinobufotin injection combined with transcatheter arterial chemoembozilation. *Modern Journal of Integrated Traditional Chinese and Western Medicine*, 15, 1313–1314 (2006).

70. Wu, J. S., Wei, Y. F. & Hoo, Z. G. et al. The side effect evaluation of Aiyishu injection injection combined with half amount of transcatheter arterial chemoembozilation for hepatocellular carcinoma. *Neimeineng Traditional Chinese Medicine*, 7, 66–67 (2015).

71. Wu, Z. M., Liu, Q. & Qi, X. H. Efficacy of cantharidin combined with transcatheter arterial embozilation for primary hepatocellular carcinoma. *Journal of Southern Medical University*, 30, 2774–2776 (2010).

72. Xiao, X. S. Fifty cases clinical observation for the advanced liver cancer by cantharidin combined with transcatheter arterial embozilation. *China Foreign Medical Treatment*, 25, 88–89 (2011).

73. Xie, J., Wang, Z. R. & Ma, L. et al. Fifty cases clinical study of Xin Feng Chinese medicine combined transcatheter arterial embozilation for liver cancer treatment. *Jiangsu Traditional Chinese Medicine*, 47, 32–33 (2015).

74. Xie, Y. F., Tan, X. F. & Ma, Q. H. et al. Clinical observation: Jinlong capsule combined transcatheter arterial embozilation for liver cancer treatment. *Chinese Journal of Clinical Oncology*, 30, 297–298 (2003).

75. Xu, Y. S., Meng, Q. S., Su, F. & Zhao, T. B. Clinical study of sodium norcantharidin combined with transcatheter hepatic arterial chemoembozilation as treatment for advanced liver cancer. *Medical Recaptitulate*, 17, 2088–2099 (2011).

76. Xue, Q., Lu, L. Q., Yuan, G. R. & Zhao, T. W. Thirty-two cases clinical study for middle and end-stage primary liver cancer across cantharidin combined with transcatheter arterial embozilation. *Jiangsu Traditional Chinese Medicine*, 42, 22–24 (2010).

77. Yang, P. Y., Sun, Y. Y. & Zhang, Y. C. et al. Effectiveness of early intervention with Jin-long capsules and transarterial chemoembozilation for the treatment of primary liver cancer. *Chinese Journal Clinical Oncology*, 40, 45–49 (2013).

78. You, S. Y., Fan, H. & Huan, Z. G. et al. Clinical study of cantharidin injection combined with transcatheter arterial embozilation for middle and end-stage liver cancer. *Hebei Medicine*, 12, 1096–1100 (2006).

79. Yu, J. G. Clinical observation for primary hepatocellular carcinoma by cantharidin injection combined with transcatheter arterial embozilation. *Modern Digestion & Intervention*, 18, 32–33 (2013).

80. Yuan, C. Y., Xie, Q. & Xie, B. R. et al. Twenty cases clinical observation of cantharidin injection combined with transcatheter arterial embozilation by primary liver cancer. *Guiding Journal of Traditional Chinese Medicine and Pharmacy*, 17, 16–17 (2011).

81. Zhang, B. Clinical observation of Aiyishu injection combined with transcatheter arterial embozilation for primary liver cancer. *China Medical Herald*, 4, 48–49 (2007).

82. Zhang, C. Q., Liang, T. J. & Yuan, M. B. Clinical studies of the combination therapy with Jinlong capsule and chemical therapy and embozilation by hepatic artery catheterization on primary hepatic carcinoma. *Beijing Medical Journal*, 27, 357–359 (2005).

83. Zhang, M. J. & Zuo, C. F. Clinical efficacy of sodium cantharidate vitamin B6 injection combined with chemotherapy in treatment of liver cancer. *Journal of Practical Oncology*, 26, 50–52 (2011).

84. Zhang, T. S. & Shan, G. Z. Continuous transarterial infusion with cinobufotin combined with transhepatic arterial embolism in the treatment of 32 cases with primary hepatocellular carcinoma. *Journal of China Oncology*, 17, 557–558 (2011).

85. Zhou, J. S., Lu, H., Wu, X. D. & Xu, X. Clinical observation of Huachansu injection combined transarterial infusion therapy for primary liver cancer. *Chinese Journal of Primary Medicine and Pharmacy*, 13, 571–572 (2006).

86. Zhu, W. Q. Sodium cantharidinate and vitamin B6 injection in combination with TACE for p rim ary liver cancer. *International Journal of Internal Medicine and Health Guidance News*, 20, 2130–2132 (2014).

87. Angell, M. Negative studies. *New England Journal of Medicine*, 321, 464–466 (1989).

88. Germani, G. et al. Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetate injection for hepatocellular carcinoma: a Meta-analysis. *Journal of Hepatology*, 52, 380–388 (2010).

89. Yang, J. D. & Roberts, L. R. Hepatocellular carcinoma: A global view. *Nature Reviews Gastroenterology & Hepatology*, 7, 448–458 (2010).

90. Beggs, C. B. A measure to aid in the interpretation of published clinical trials. *Statistical in Medicine*, 4, 1–9 (1985).

91. Dickersin, K., Min, Y. I. & Meinert, C. L. Factors influencing publication of research results: follow-up of applications submitted to two institutional review boards. *JAMA*, 267, 374–378 (1992).

Acknowledgements
This article was supported by the Youth Science Fund Project of China National Natural Science Foundation (NO. 81403292); the Natural Science Basic Study Project of Shannxi Province (NO. 2015Q8290) and the Boosting Project of Xijing Hospital (NO. XJZT13M18).

Author Contributions
All authors have contributed to this article. The databases were searched and data were extracted by Z.F.S., J.X., Y.Q.Y. The statistical analysis was conducted by Z.F.S. and modified by L.S. and Y.W. The study tables and figures were conducted by Z.F.S. and T.B.S. The article language was edited and revised by K.K.S. and Y.W. The basic knowledge of TCM was guided by Y.P.D.

Additional Information
Supplementary information accompanies this paper at doi:10.1038/s41598-017-04351-y

Competing Interests: The authors declare that they have no competing interests.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2017